Boston Scientific Corporation (BSX)
Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
Boston Scientific's shares have fallen over 50% year to date as the medtech company continues to walk back full-year 2026 guidance. Sell-side analysts remain relatively upbeat on the stock.
Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One
Boston Scientific has experienced a ~53% collapse over twelve months, driven by guidance cuts, WATCHMAN deceleration, EP share loss, and a mixed CHAMPION-AF readout. FY26 guidance was cut to 6.5-8.0% organic growth and $3.34-$3.41 EPS, with management tempering long-term 10%+ growth expectations. BSX trades at a significant discount to peers (12.6x FY27E P/E), despite maintaining a robust ~8% revenue and ~10-11% EPS growth profile.
Boston Scientific (BSX) Rises Higher Than Market: Key Facts
Boston Scientific (BSX) concluded the recent trading session at $48.85, signifying a +2.43% move from its prior day's close.
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Why These Three Big Buybacks Are Sending Very Different Signals to Investors
Share buybacks are one of the key ways that companies express confidence in their outlook. This is particularly true when shares take a large hit, as management teams look to retire shares at what they may believe is a depressed price.
Boston Scientific Corporation (BSX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Boston Scientific Corporation (BSX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
BSX vs. ABT: Which Medical Stock Has More Upside Potential?
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
Boston Scientific (BSX) concluded the recent trading session at $49.11, signifying a -2.68% move from its prior day's close.
Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth
WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.
Why Is Boston Scientific (BSX) Down 13% Since Last Earnings Report?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Boston Scientific: A Rare 40% Drawdown Creates A Buying Opportunity
Boston Scientific is down over 43% YTD, erasing years of gains amid guidance cuts and segment-specific weakness. I initiate BSX with a Buy rating, citing achievable guidance post-Q1 reset and easing sales comps in 2H, which could stabilize the stock. Key risks include further guidance cuts, persistent WATCHMAN and Urology segment weakness, and macro-driven procedure slowdowns.
